Dr. Rossomando, PhD, joins Anokion as vice president of technical operations and leads all aspects of the company’s CMC activities. Tony brings over 25 years of industry experience to Anokion and most recently was head of analytical development at Alexion, following its acquisition of Synageva Biopharma, where he oversaw the entire pipeline of development stage projects through phase 2. Prior to Synageva, he held positions of increasing responsibility at Alnylam Pharmaceuticals, Biogen, and Bayer Corp. He was instrumental in two successful IND submissions for neuropathic pain and mucopolysaccharidosis IIIB and played a pivotal role in the approval of Kanuma® for Lysosomal Lipase Deficiency in the United States, Europe, and Japan. Tony received his B.S. from SUNY Stony Brook and his PhD in microbiology from the University of Virginia and completed post-doctoral training at Cold Spring Harbor where he focused on cell-signaling control mechanisms and protein sciences.